Byotrol PLC AGM Statement (1961F)
November 13 2020 - 2:00AM
UK Regulatory
TIDMBYOT
RNS Number : 1961F
Byotrol PLC
13 November 2020
Byotrol plc
AGM STATEMENT
Byotrol plc (AIM: BYOT), the specialist infection prevention and
control company, makes the following statement ahead of the
Company's AGM later today.
The Directors are pleased to report that trading remains at
healthy levels, across all business units and product sales. Demand
for IP licensing remains robust, with the team exploring multiple
new opportunities both in the UK and internationally.
The Group's net cash position remains strong, enabling us to
maintain stock levels to fulfil customer demand or where
appropriate re-invest for the growth of the business.
We expect results for the year to 31 March 2021 to meet current
market expectations, notwithstanding the recent news on the
development of potential vaccines against Covid-19. This is
supported by industry trends clearly in evidence before (and now
magnified by) Covid-19, all of which continue to favour Byotrol's
long-term positioning, notably:
-- businesses and consumers taking increasingly proactive
responsibility for protecting individuals against infection risk
from viruses and bacteria, so increasing global demand; and
-- competitors with weaker performance chemistries continuing to
withdraw from our market in the UK and Europe as new regulations
take hold, so reducing the supply of competing products and so
multiplying opportunities for Byotrol's future growth.
The Directors remain highly confident in Byotrol's longer term
outlook.
Enquiries:
Byotrol plc
David Traynor, Chief Executive Officer
Nic Hellyer, Chief Financial Officer 01925 742 000
finnCap
Geoff Nash/Kate Bannatyne - Corporate Finance 020 7220 0500
Richard Chambers - ECM
Flagstaff Strategic and Investor Communications
Tim Thompson/Andrea Seymour/Fergus Mellon 020 7129 1474
byotrol@flagstaffcomms.com
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection
prevention and control company, operating globally in the
Healthcare, Industrial, Food and Consumer sectors, providing low
toxicity products with a broad-based and targeted efficacy across
all microbial classes; bacteria, viruses (including coronavirus),
fungi, moulds, mycobacteria and algae.
Byotrol's products can be used stand-alone or as ingredients
within existing products, where they can significantly improve
their performance, especially in personal hygiene, domestic and
industrial disinfection, odour control, food production and food
management.
Byotrol develops and commercialises technologies that create
easier, safer and cleaner lives for everyone.
For more information, please go to byotrol.co.uk
This announcement is released by Byotrol plc and, prior to
publication, the information contained herein was deemed to
constitute inside information under the Market Abuse Regulations
(EU) No. 596/2014. Such information is disclosed in accordance with
the Company's obligations under Article 17 of MAR.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGMFLFETLELFLII
(END) Dow Jones Newswires
November 13, 2020 02:00 ET (07:00 GMT)
Byotrol (LSE:BYOT)
Historical Stock Chart
From Apr 2024 to May 2024
Byotrol (LSE:BYOT)
Historical Stock Chart
From May 2023 to May 2024